Two additional countries opted to suspend the use of the AstraZeneca vaccine in Europe on Tuesday as regulators proceeded with a new review into its side effects.
U.K. tech start-ups raised a record $15 billion from venture capitalists in 2020, widening its gap with Germany and France, according to a Tech Nation report.
The WHO has sought to downplay safety concerns, saying last week that there is no link between the shot and an increased risk of developing blood clots.
Six European Union countries have raised concerns over how the bloc is distributing Covid-19 vaccines, after AstraZeneca cut its delivery targets once again.
AstraZeneca has said the vaccine has been studied extensively during Phase 3 trials and peer-reviewed data confirms the shot is "generally well tolerated."
The European Union has asked AstraZeneca to do more to respect its contract with the bloc, as concerns grow that the firm will miss delivery targets once again.
Get complete CNBC business news coverage online. Find the latest business news pertaining to Europe. Sector watch news, headlines; top stories is available on the official CNBC Europe site.